| | | | | | | | | | |
|
|
|
| Dockets Entered
On August 11, 2006
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
|
|
| 2003N-0312
|
| Discussion of Animal Feed Safety System (AFSS): A Comprehensive Risk-Based Safety Program for the Manufacture and Distribution of Animal Feeds
|
|
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
|
|
| 2006N-0107
|
| FDA-Regulated Products Containing Nanotechnology Materials
|
|
|
|
|
| 2006N-0292
|
| Unique Device Identification
|
|
|
|
|
| 2006P-0071
|
| 513 (e) Reclassification of Tissue Adhesive For Soft Tissue Approximation
|
|
|
|
|
| 2006P-0151
|
| Stay the current approvable letter with conditions of any and all Premarket Applications for silicone gel-filled breast implants
|
|
|
|
|
| 2006P-0158
|
| Revoke regulations that provided for the inclusion and addition of sucralose as a non-nutritive sweetener in food
|
|
|
|
|
| 2006P-0223
|
| Switch Plan B and equivalent EC drugs from prescription-only to OTC status without age restrictions, exempt from prescription -dispensing requirement any new drug eligible for filing an ANDA
|
|
|
|
|
| 2006P-0319
|
| Regarding review of policies and practices of DDMAC and OCBQ to ensure compliance with first amendment and statutory mandate
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| LET 18021
|
| WN Pharmaceuticals, Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18022
|
| WN Pharmaceuticals, Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18023
|
| WN Pharmaceuticals, Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18024
|
| WN Pharmaceuticals, Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18025
|
| WN Pharmaceuticals, Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18026
|
| WN Pharmaceuticals, Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18027
|
| WN Pharmaceuticals, Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18028
|
| WN Pharmaceuticals, Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18029
|
| WN Pharmaceuticals, Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18030
|
| WN Pharmaceuticals, Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18031
|
| Nature's Way Products Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18032
|
| BSp Pharma Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18033
|
| New Century Company
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18034
|
| Pharmavite LLC
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18035
|
| Garden of Life Inc
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18036
|
| Source Naturals
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18037
|
| Source Naturals
|
| Vol #:
|
| 166
|
|
|
|
|
| LET 18038
|
| Neways International
|
| Vol #:
|
| 166
|
|
| |
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
|
|
| EMC 687
|
| Calorie Control COuncil
|
| Vol #:
|
| 687
|
|
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
|
|
|
|
|
|
|
|
| |
| |
|
| 2006N-0292
|
| Unique Device Identification
|
|
|
|
|
| BKG 1
|
| Background Material
|
| Vol #:
|
| 2
|
|
|
|
|
| N 1
|
| FDA
|
| Vol #:
|
| 1
|
|
| |
|
| 2006P-0071
|
| 513 (e) Reclassification of Tissue Adhesive For Soft Tissue Approximation
|
|
|
|
|
| C 2
|
| Tyco Healthcare Group, LP
|
| Vol #:
|
| 2
|
|
|
|
|
| 2006P-0151
|
| Stay the current approvable letter with conditions of any and all Premarket Applications for silicone gel-filled breast implants
|
|
|
|
|
| EC 689
|
| Mrs. Bonnie Gibson
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 690
|
| Mrs. Alice Langton
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 691
|
| Mr. Ed Brent
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 692
|
| Mrs. Susan Boone
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 693
|
| Ms. Ruby Rahn
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 694
|
| Ms. M M
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 695
|
| Ms. Melinda Ault
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 696
|
| Ms. Cynthia Reeves
|
| Vol #:
|
| 3
|
|
|
|
|
| 2006P-0158
|
| Revoke regulations that provided for the inclusion and addition of sucralose as a non-nutritive sweetener in food
|
|
|
|
|
| EMC 34
|
| K. Kenney
|
| Vol #:
|
| 1
|
|
|
|
|
| EMC 35
|
| K. Houston
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0223
|
| Switch Plan B and equivalent EC drugs from prescription-only to OTC status without age restrictions, exempt from prescription -dispensing requirement any new drug eligible for filing an ANDA
|
|
|
|
|
|
|
|
|
| EMC 25
|
| M. Roets
|
| Vol #:
|
| 2
|
|
|
|
|
| EMC 26
|
| S. Hornack
|
| Vol #:
|
| 2
|
|
|
|
|
| 2006P-0319
|
| Regarding review of policies and practices of DDMAC and OCBQ to ensure compliance with first amendment and statutory mandate
|
|
|
|
|
| ACK 1
|
| FDA/DDM to Washington Legal Foundation
|
| Vol #:
|
| 1
|
|
|
|
|
| CP 1
|
| Washington Legal Foundation
|
| Vol #:
|
| 1
|
|
